Skip to main content

Sarcoidosis clinical trials at UCSF

2 research studies open to eligible people

Sarcoidosis is a disease that can affect many parts of your body. At UCSF, we are studying how genes and the environment can trigger this disease. We are also testing a gel called Acthar to see if it can improve lung function and symptoms.

Showing trials for
  • CXCL9 as a Biomarker of Acthar Efficacy

    open to eligible people ages 18-65

    The objective is this study is to test whether use of Acthar gel in the context of sarcoidosis will lead to improved symptoms and lung function and correlate with decreased levels of predictive blood biomarkers, like chemokine ligand 9 (CXCL9).

    San Francisco, California

  • Epigenetic Regulation of Altered T-cell Immunity in Sarcoidosis

    open to eligible people ages 18-85

    Sarcoidosis is a multi-system granulomatous disorder that is triggered and influenced by gene-environment interactions. Although sarcoidosis predominantly affects the lungs in most cases, the clinical disease course is highly variable and any organ can be affected leading to end organ damage despite currently available therapeutics that unfortunately also have numerous and potentially devastating side effects. The environmental triggers of sarcoidosis are unknown but several occupational, environmental and infectious agents have been associated with sarcoidosis in susceptible hosts. Exposure to these triggers result in inflammation, characterized by activation of CD4+ T-cells, cytokine production, subsequent recruitment of other immune cells, and granuloma formation. Although several genetic markers have been associated with sarcoidosis, none fully explain individual susceptibility or clinical course variability, strongly implicating the environment and epigenetics. We have the ability to generate a map of the epigenetic histone modifications in immune cells via Chromatin Immuno-Precipitation coupled with next generation sequencing (ChIP-seq) and a map of transcriptome profiles via RNA-seq. The availability of histone and transcriptional signatures defining T cell activity in sarcoidosis will help identify the specific molecular programs affected by disease processes and can become the basis for future discovery of novel biomarker diagnostics in a clinical setting.

    San Francisco, California

Our lead scientists for Sarcoidosis research studies include .

Last updated: